Linkedin
RLS logo_header
Linkedin

Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production

“Actinium-225 represents a transformative opportunity in the realm of cancer treatment. As we look ahead, the global demand for Ac-225 is poised to rise sharply, driven by the urgent need for innovative therapies that can target hard-to-reach tumors and metastases.” said Dr. Andrew Cavey, CEO, ITM and Actineer Board Chairman. “Actineer is leading the effort to deliver a stable and scalable supply of Ac-225 which is essential for advancing clinical trials and also for making life-saving treatments accessible to patients worldwide.”

Read the full story on "Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production"

Share:

More News

Strong Initial Efficacy Data Reported in 3L NSCLC from Ph 2 THIO-101 Part C Expansion Trial 

“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy

FDA Clears IND for UGN-501 for Non-Muscle Invasive Bladder Cancer

“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality

Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data